Persivia vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $107M strategic (May 2025) from Aldrich Capital. 200+ hospitals, 12,000+ clinicians. Patented Soliton AI engine. Global expansion in 2026. Spans care management, population health, and RCM.
About
Persivia is a unified AI healthcare platform spanning care management, population health analytics, and revenue cycle operations — one of the few integrated platforms that addresses both the clinical and financial sides of health system performance simultaneously. The company raised $107 million in strategic financing from Aldrich Capital Partners in May 2025, and is actively expanding globally in 2026 with its CareSpace platform deployed at 200+ hospitals and used by 12,000+ clinicians.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.